T2 Biosystems, Inc. (TTOO)
USD 0.35
(2.88%)
USD 0.35
(2.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 34.79 Million USD | 1.18% |
| 2022 | 34.39 Million USD | -43.19% |
| 2021 | 60.53 Million USD | -23.44% |
| 2020 | 79.07 Million USD | 177.6% |
| 2019 | 28.48 Million USD | -55.7% |
| 2018 | 64.3 Million USD | 17.22% |
| 2017 | 54.86 Million USD | -38.75% |
| 2016 | 89.56 Million USD | 3.01% |
| 2015 | 86.94 Million USD | 10.31% |
| 2014 | 78.82 Million USD | 147.2% |
| 2013 | 31.88 Million USD | 178.93% |
| 2012 | 11.43 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 21.72 Million USD | -12.26% |
| 2024 Q1 | 24.75 Million USD | -28.86% |
| 2023 Q4 | 34.79 Million USD | -19.6% |
| 2023 Q3 | 43.28 Million USD | 16.57% |
| 2023 Q1 | 32.73 Million USD | -4.82% |
| 2023 Q2 | 37.13 Million USD | 13.44% |
| 2023 FY | 34.79 Million USD | 1.18% |
| 2022 Q2 | 39.6 Million USD | -19.24% |
| 2022 Q3 | 43.95 Million USD | 10.98% |
| 2022 Q4 | 34.39 Million USD | -21.75% |
| 2022 FY | 34.39 Million USD | -43.19% |
| 2022 Q1 | 49.03 Million USD | -19.0% |
| 2021 Q1 | 70.05 Million USD | -11.41% |
| 2021 Q3 | 70.03 Million USD | -11.23% |
| 2021 Q4 | 60.53 Million USD | -13.56% |
| 2021 Q2 | 78.89 Million USD | 12.63% |
| 2021 FY | 60.53 Million USD | -23.44% |
| 2020 Q3 | 77.63 Million USD | 44.53% |
| 2020 Q4 | 79.07 Million USD | 1.86% |
| 2020 FY | 79.07 Million USD | 177.6% |
| 2020 Q1 | 51.35 Million USD | 80.27% |
| 2020 Q2 | 53.71 Million USD | 4.6% |
| 2019 Q1 | 55.55 Million USD | -13.61% |
| 2019 FY | 28.48 Million USD | -55.7% |
| 2019 Q3 | 34.25 Million USD | -24.17% |
| 2019 Q2 | 45.17 Million USD | -18.69% |
| 2019 Q4 | 28.48 Million USD | -16.84% |
| 2018 Q1 | 42.11 Million USD | -23.23% |
| 2018 Q2 | 84.21 Million USD | 99.94% |
| 2018 Q3 | 75.89 Million USD | -9.88% |
| 2018 Q4 | 64.3 Million USD | -15.27% |
| 2018 FY | 64.3 Million USD | 17.22% |
| 2017 Q3 | 69.67 Million USD | 9.25% |
| 2017 FY | 54.86 Million USD | -38.75% |
| 2017 Q4 | 54.86 Million USD | -21.27% |
| 2017 Q2 | 63.77 Million USD | -15.7% |
| 2017 Q1 | 75.65 Million USD | -15.53% |
| 2016 Q2 | 65.9 Million USD | -12.05% |
| 2016 Q3 | 92 Million USD | 39.59% |
| 2016 Q4 | 89.56 Million USD | -2.65% |
| 2016 FY | 89.56 Million USD | 3.01% |
| 2016 Q1 | 74.93 Million USD | -13.81% |
| 2015 Q2 | 63.71 Million USD | -12.45% |
| 2015 Q1 | 72.77 Million USD | -7.67% |
| 2015 Q3 | 53.12 Million USD | -16.62% |
| 2015 Q4 | 86.94 Million USD | 63.67% |
| 2015 FY | 86.94 Million USD | 10.31% |
| 2014 Q4 | 78.82 Million USD | -0.06% |
| 2014 Q3 | 78.86 Million USD | 293.31% |
| 2014 Q2 | 20.05 Million USD | -38.22% |
| 2014 FY | 78.82 Million USD | 147.2% |
| 2014 Q1 | 32.45 Million USD | 1.79% |
| 2013 Q4 | 31.88 Million USD | 0.0% |
| 2013 FY | 31.88 Million USD | 178.93% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 11.43 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bionano Genomics, Inc. | 214.4 Million USD | 83.77% |
| Prenetics Global Limited | 254.17 Million USD | 86.31% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 59.991% |
| CareDx, Inc | 484.61 Million USD | 92.82% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.462% |
| Exagen Inc. | 56.94 Million USD | 38.893% |
| Inotiv, Inc. | 856.53 Million USD | 95.937% |
| Guardant Health, Inc. | 1.78 Billion USD | 98.052% |
| Biodesix, Inc. | 99.09 Million USD | 64.886% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -205.242% |
| Precipio, Inc. | 18.1 Million USD | -92.238% |
| iSpecimen Inc. | 15.81 Million USD | -119.968% |
| Natera, Inc. | 1.45 Billion USD | 97.612% |
| Aspira Women's Health Inc. | 6.26 Million USD | -455.685% |
| Standard BioTools Inc. | 323.06 Million USD | 89.229% |
| 23andMe Holding Co. | 395.16 Million USD | 91.194% |
| Castle Biosciences, Inc. | 477.81 Million USD | 92.717% |
| Personalis, Inc. | 225.09 Million USD | 84.541% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 82.373% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -154.894% |
| OpGen, Inc. | 1.88 Million USD | -1748.668% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 97.097% |
| ICON Public Limited Company | 16.98 Billion USD | 99.795% |
| NeoGenomics, Inc. | 1.68 Billion USD | 97.93% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 59.991% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 98.933% |
| RadNet, Inc. | 2.88 Billion USD | 98.795% |
| MDxHealth SA | 129.13 Million USD | 73.053% |
| Psychemedics Corporation | 13.27 Million USD | -162.223% |
| Illumina, Inc. | 10.11 Billion USD | 99.656% |
| Check-Cap Ltd. | 25.01 Million USD | -39.093% |
| Twist Bioscience Corporation | 776.4 Million USD | 95.518% |
| DarioHealth Corp. | 96.38 Million USD | 63.899% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 97.267% |
| Sera Prognostics, Inc. | 95.44 Million USD | 63.541% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -415.195% |
| OPKO Health, Inc. | 2.01 Billion USD | 98.27% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 97.9% |
| Neogen Corporation | 4.58 Billion USD | 99.241% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -152.539% |
| Prenetics Global Limited | 254.17 Million USD | 86.31% |
| Mainz Biomed B.V. | 15.4 Million USD | -125.822% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -323.241% |
| Trinity Biotech plc | 59.43 Million USD | 41.454% |
| Neuronetics, Inc. | 115.83 Million USD | 69.959% |
| Sotera Health Company | 3.13 Billion USD | 98.888% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -323.241% |